WASHINGTON, D.C.—Nocturia is the most common overactive bladder (OAB) symptom affecting health-related quality of life (HRQL) in patients with postural tachycardia syndrome (POTS), investigators reported at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Overactive bladder (OAB) symptoms are common in patients with Parkinson’s disease regardless of age and gender, and the severity of Parkinson’s symptoms correlates with OAB symptoms, according to a study presented at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Prostate cancer (PCa) patients found to have extracapsular extension after radical prostatectomy have a greater risk of biochemical recurrence (BCR) recurrence 10 years after surgery, researchers reported at the American Urological Associatoin 2011 annual meeting.
WASHINGTON, D.C.—Active surveillance for screen-detected localized prostate cancer (PCa) does not increase the risk of death from prostate cancer (PCa) relative to definitive local treatment, according to study findings presented at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Robot-assisted radical prostatectomy (RARP) for localized prostate cancer (PCa) offers favorable intermediate- and long-term oncologic outcomes, researchers reported at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Elevation of serum leptin and a decrease in monocyte chemotactic protein-1 (MCP-1) levels are associated with overactive bladder (OAB) symptoms, according to new data presented at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Renal masses greater than 4 cm in diameter tend to grow faster than smaller masses, a researcher reported at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—African-American race and older age are risk factors for development of proteinuria in men who receive androgen deprivation therapy (ADT) for prostate cancer (PCa), according to data presented at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Sacral neuromodulation with InterStim Therapy is safe and well tolerated as a treatment for patients with overactive bladder and those with urinary retention, French investigators reported at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Adverse events (AEs) after intravesical botulinum toxin type A for idiopathic detrusor overactivity (IDO) are encountered frequently, according to a new study presented at the American Urological Association 2011 annual meeting.
Please login or register first to view this content.
